Efficacy News and Research

RSS

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).

17 Jul 2012

Once-daily single-tablet HIV therapy developed

A single tablet containing four antiviral agents may be an effective initial once-daily therapy for adults infected with HIV, shows phase III clinical research.

16 Jul 2012

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

Merck, known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer's Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012.

16 Jul 2012

Polio eradication: an interview with Dr. Kathleen O’Reilly

Polio is a disease caused by a virus and results in paralysis, usually in the legs, of those affected. The paralysis is irreversible. In some extreme cases the virus spreads to the nerve cells of the brain reducing breathing capacity and this rarer form can be fatal.

16 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

New paper documents discovery of novel lipids, including MC3

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and collaborators announced today the publication of a scientific paper documenting the discovery of novel lipids used in second generation lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

14 Jul 2012

EU-funded researchers develop new antimicrobial resistance monitoring solution

Every year hundreds of thousands of people die because of infections that have become resistant to treatment. A new data-mining, clinical monitoring and decision-support system, developed by EU-funded researchers, offers a powerful new weapon in the war on resistance to antibiotics.

14 Jul 2012

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.

13 Jul 2012

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

Cubist Pharmaceuticals, Inc. today announced the initiation of its pivotal Phase 3 studies evaluating the efficacy and safety of CB-315 in patients with Clostridium difficile-associated diarrhea, or CDAD, with enrollment of a patient in the first of two planned identical global trials.

13 Jul 2012

Pressure Point develops 72 hour low-cost dermal device to effectively reduce PONV

Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.

12 Jul 2012

Eschar-derived cells may be used for tissue engineering

A research team in the Netherlands has found that cells from burn eschar, the non-viable tissue remaining after burn injury and normally removed to prevent infection, can be a source of mesenchymal cells that may be used for tissue engineering.

12 Jul 2012

Merck announces update on odanacatib Phase III trial for osteoporosis

Merck, known as MSD outside the United States and Canada, announced today an update on the Phase III trial assessing fracture risk reduction with odanacatib, Merck's investigational cathepsin K (cat-K) inhibitor.

12 Jul 2012

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.

12 Jul 2012

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.

12 Jul 2012

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain.

12 Jul 2012

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1.

12 Jul 2012

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Among intermediate- to high-risk patients undergoing coronary artery bypass graft surgery, administration of the agent acadesine to regulate adenosine (a naturally occurring chemical that dilates blood flow and can improve coronary blood flow and perfusion) did not reduce all-cause death, nonfatal stroke, or need for mechanical support for ventricular dysfunction, for approximately a month after surgery, according to a study in the July 11 issue of JAMA.

12 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BioInvent International AB today announced data from the GLACIER phase IIa study evaluating BI-204 in patients with stable atherosclerotic vascular disease. BioInvent is developing BI-204 in collaboration with Genentech, a member of the Roche Group.

11 Jul 2012

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

Efficacy News and Research

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

Once-daily single-tablet HIV therapy developed

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

Polio eradication: an interview with Dr. Kathleen O’Reilly

UCB’s Neupro now available in U.S. pharmacies

New paper documents discovery of novel lipids, including MC3

EU-funded researchers develop new antimicrobial resistance monitoring solution

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

Pressure Point develops 72 hour low-cost dermal device to effectively reduce PONV

Eschar-derived cells may be used for tissue engineering

Merck announces update on odanacatib Phase III trial for osteoporosis

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Arrowhead initiates Adipotide Phase 1 trial in obesity

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News